While much development is required, we propose that the combined gene transfer approach of IFNβ with p14ARF will bring superior clinical benefit not seen with IFNβ biochemotherapy or gene therapy strategies that are only focused in killing tumor cells without activating an immune response. This evidence concerns the gene IFNB1 and neoplasm.